Home > Insider Trading > Filing (0001387131-23-000335)

Filing Details

Accession Number:: 0001387131-23-000335
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-01-13 16:19:44
Reporting Period:: 2022-12-23

Accepted Time:: 2023-01-13 16:19:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601830	Recursion Pharmaceuticals Inc.	RXRX	()	C0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1419351	Pjsc Holding Global Diversified Mamoura	P. O. Box 45005 Abu Dhabi C0 UAE		No	No	Yes	No
1704268	Mubadala Investment Co Pjsc	P.o. Box 45005 Abu Dhabi C0 00000		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2022-12-23	100,378	$7.52	11,392,315	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2022-12-27	145,652	$7.24	11,537,967	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2022-12-28	71,299	$7.18	11,609,266	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2022-12-29	84,622	$7.71	11,693,888	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2022-12-30	99,754	$7.55	11,793,642	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2023-01-03	141,646	$7.50	11,935,288	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2023-01-04	91,892	$7.80	12,027,180	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2023-01-05	80,035	$7.38	12,107,215	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2023-01-06	68,953	$7.41	12,176,168	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2023-01-09	76,046	$7.64	12,252,214	No	4	P	Indirect	See Explanation of Responses
Class A Common Stock	Acquisiton	2023-01-10	69,518	$7.72	12,321,732	No	4	P	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	7,062,869	Indirect	See Explanation of Responses

Footnotes

This is an inadvertent late filing due to an administrative error.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.70, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (12) to this Form4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.61, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.32, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.25 to $7.91, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.72, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.83, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.88, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.75, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $8.00, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $8.00, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $8.00, inclusive.
Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.
MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.
Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.